Evidence map›Paper›PMID 39330378›Full record

ArticleJournal of fungi (Basel, Switzerland)2024

In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four

Dávid Balázsi, Zoltán Tóth, Jeffrey B Locke, Andrew M Borman, Lajos Forgács, Noémi Balla, Fruzsina Kovács, Renátó Kovács, Chiaki Amano, Tugba Ilay Baran and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Recent Outbreaks, Resistance Trends, and Control Measures inJournal of fungi (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dávid BalázsiMedical Microbiology, Clinical Center, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Zoltán TóthMedical Microbiology, Clinical Center, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Jeffrey B LockeCidara Therapeutics, Inc., 6310 Nancy Ridge Dr., Suite 101, San Diego, CA 92121, USA.ORCID 0000-0001-8145-0828
Andrew M BormanUK National Mycology Reference Laboratory, UK Health Security Agency, Science Quarter, Southmead Hospital, Bristol BS10 5NB, UK.ORCID 0000-0003-0585-5721
Lajos ForgácsMedical Microbiology, Clinical Center, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Noémi BallaMedical Microbiology, Clinical Center, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Fruzsina KovácsMedical Microbiology, Clinical Center, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Renátó KovácsMedical Microbiology, Clinical Center, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.ORCID 0000-0003-3946-2424
Chiaki AmanoMedical Microbiology, Clinical Center, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Tugba Ilay BaranMedical Microbiology, Clinical Center, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
László MajorosMedical Microbiology, Clinical Center, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Funding

Hungarian Academy of Sciences BO/00127/21/8National Research, Development and Innovation Fund UNKP-23-4-II-DE-73National Research, Development and Innovation Fund UNKP-23-5-DE-480National Research, Development and Innovation Office FK138462
6 · The paper itself

Abstract

objectivesRezafungin is the first new drug approved to treat candidaemia and invasive candidiasis in more than 10 years. However, data are scant on the in vivo efficacy of rezafungin and the other three approved echinocandins against different

methodsThis study involved 10 isolates representing 4

resultsRegardless of isolate and clade, all echinocandin regimens improved survival after 21 days (

conclusionsRegardless of the

Indexed as

Candida aurisechinocandinsmurine model

Identifiers

PMID39330378
PMCPMC11433204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.